Symbiotec Pharmalab IPO

Symbiotec Pharmalab Ltd. filed DRHP on December 19 2025, for its upcoming IPO, which is 100% book-built issue. This IPO is a combination of a fresh issue of ₹150 crore and an offer for sale (OFS) of ₹2,030 crore.

Major firms have seen in this IPO, which includes JM Financial Ltd., Avendus Capital Private Ltd., Motilal Oswal Investment Advisors Ltd. and Nomura Financial Advisory and Securities (India) Private Ltd. The registration process is served by MUFG Intime India Private Ltd. for the Symbiotec Pharmalab IPO. At this preliminary stage, key logistical details such as the price band, specific bidding dates and the expected listing date remain to be announced.

Company Background

Symbiotec Pharmalab Ltd. is located in Indore, Madhya Pardesh and was incorporated on September 20, 2002. The company has undergone several corporate transitions, eventually converting into a public company in September 2025 to facilitate its strategic vision for future expansion.

With professional management and an experienced team, they transform themselves from the local manufacturer into a significant global player in the API industry. Symbiotec Pharmalab Ltd. specializes in the research, development and manufacturing of high-quality steroid and hormone-based APIs and intermediates, catering to a diverse clientele in both domestic and international markets.

Operations and Product Range

The operations of Symbiotec Pharmalab Ltd. center around being an integrated API and intermediate provider. The company’s portfolio is highly specialized, focusing on products that require complex fermentation and chemical synthesis processes.

• • Primary solutions are the manufacturing and selling of steroid-based APIs, hormone APIs and their related intermediates.
• • A global customer base, with a presence in major markets including the USA, China and Singapore.
• • Their products are used in various therapeutic areas, supporting pharmaceutical companies that produce life-saving medications and hormone-related treatments.

Facilities and Capacity

The company operates from its primary registered and corporate facility located in Rau, Mhow, Indore. This integrated hub houses its manufacturing units, research and development centers and administrative offices.

A significant portion of the company’s current focus is on "Greenfield projects," which include new facilities under its subsidiaries, Knovea Pharmaceutical Private Limited and Symbiotec Zenfold Private Limited. These expansion plans are intended to significantly scale production capacity and enhance the company's ability to handle high-volume global contracts.

Brands and Market Presence

Under the "SYMBIOTEC" brand, the company has established a remarkable presence in the specialized API segment of the market. Symbiotec Pharmalab Ltd. of the few Indian companies with deep technical expertise in both chemical and fermentation-based steroid manufacturing. Key market presence points are:

• • Strong international footprint by exports with subsidiaries in Singapore, China and the USA.
• • A certified engineering firm (relevant to its technical manufacturing standards) that maintains high-quality, health and safety standards essential for the global pharma industry.

Revenue Streams and Business Model

Symbiotec Pharmalab Ltd.’s revenue streams are diversified across various segments and geographies, ensuring multiple income channels. Key sources of income are:

• • API & Intermediate sales accounted for the bulk of the ₹7,515.54 million generated in Fiscal 2025.
• • Revenue generation from both the Indian domestic market and a vast international export market.
• • Customer reach and strong relationships that drives sustainable portion of revenue from key customers, with the top ten clients accounting for 55.90% of product sales in Fiscal 2025.

Management and Shareholding

Promoters and Shareholding

Symbiotec Pharmalab Ltd., promoted by Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP. Before the Symbiotec Pharmalab IPO, the promoters and their group held a dominant position in the shareholding structure. Post-IPO, the equity structure will be diluted as new public investors join the cap table.

Board and Key Management

The board is led by the Chairman and Managing Director (Anil Satwani). He is supported by Non-Executive and Nominee Directors such as Rohit Mantri and Hariharnath Buggana. The leadership team also includes professional managers like Salil Jain (CS) and Giraj Daga (CFO for the group context).